Paliperidone Exeltis (Paliperidone Palmitate)

Paliperidone Palmitate, the active ingredient in Paliperidone Exeltis, is a long‑acting atypical antipsychotic presented as a depot injection for intramuscular use. It is indicated for the treatment of schizophrenia in adults and for maintenance therapy to reduce relapse. GNH USA supplies Paliperidone Exeltis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidone Exeltis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone Exeltis is an atypical antipsychotic used in the schizophrenia treatment pathway.

- Schizophrenia: Improves psychotic symptoms and reduces risk of relapse when administered as a monthly injection. - Schizoaffective disorder: Stabilises mood and psychotic features as part of a maintenance regimen. - Bipolar I disorder (maintenance): Provides long‑term mood stabilization to prevent manic or depressive episodes. - Psychotic relapse prevention: Maintains therapeutic plasma levels to minimise breakthrough psychosis. - Adjunct to oral antipsychotics: Allows dose reduction of oral agents during transition to long‑acting therapy.

Paliperidone Exeltis may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain: Discomfort at the site of administration. - Weight gain: Increase in body weight over time. - Akathisia: Restlessness or an urge to move. - Sedation: Drowsiness or reduced alertness. - Hyperprolactinemia: Elevated prolactin levels, potentially causing menstrual changes. - Constipation: Reduced bowel motility.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and rigidity. - Tardive dyskinesia: Involuntary, repetitive movements. - Seizures: Increased risk, especially in predisposed individuals. - Orthostatic hypotension: Marked blood pressure drop on standing. - Cardiac arrhythmias: QT‑interval prolongation. - Severe allergic reactions: Anaphylaxis or angio‑edema.

When prescribing Paliperidone Exeltis, clinicians should consider several safety aspects.

- Cardiovascular assessment: Evaluate for history of arrhythmias or QT prolongation. - Metabolic monitoring: Track weight, glucose, and lipid levels regularly. - Prolactin surveillance: Monitor for menstrual disturbances or galactorrhoea. - CNS effects: Observe for signs of sedation, akathisia, or extrapyramidal symptoms. - Pregnancy and lactation: Use only if benefits outweigh risks; discuss with patient. - Store at ambient temperature: Keep in original packaging, protect from moisture and direct sunlight.

Paliperidone Exeltis can interact with several drug classes; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: May increase paliperidone levels, raising toxicity risk. - QT‑prolonging agents: Combined use can exacerbate cardiac repolarisation delays. - CNS depressants: Additive sedation or respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: May enhance orthostatic hypotension. - Anticholinergic drugs: Can worsen cognitive side effects. - CYP2D6 substrates: Potential for altered metabolism of co‑administered medications.